申请人:SPOFA, Spojene Podniky Pro Zdravotnickou Vyrobu
公开号:US04678788A1
公开(公告)日:1987-07-07
N-substituted 2-chloro-7-fluoro-10-piperazino-10,11-dihydrodibenzo(b,f)thiepins are disclosed of the general formula I, ##STR1## in which R represents an aminocarbonyl, amino-oximinomethyl, 1,3-dioxolan-2-yl or 1,3-dioxan-2-yl, group and their addition salts with convenient organic and inorganic acids. These compounds are highly potent antidopaminergic, non-cataleptic neuroleptics of use in the treatment of schizophrenia. According to recent pharmacological assay results, the subject compounds are expected to be substantially free of the usual undesired extrapyramidal side effects. They can be obtained by common preparative methods from the respective starting compounds of formula III, IV or V, or also by appropriate interconversion reactions of other compounds of formula I. If required, the resulting bases are neutralized with suitable acids, preferably methanesulfonic, maleic or hydrochloric acid, to yield the corresponding addition salts that can be used in formulating proper dosage forms for pharmacological evaluation and therapeutical application.
本文公开了一般式I的N-取代2-氯-7-氟-10-哌嗪基-10,11-二氢二苯并(b,f)噻吩类化合物,其中R代表氨基甲酰基,氨基氧肟甲基,1,3-二氧杂环戊烷-2-基或1,3-二氧杂环丙烷-2-基,以及它们与方便的有机和无机酸的加合盐。这些化合物是高效的抗多巴胺能、非锥体外系副作用药物,可用于治疗精神分裂症。根据最近的药理学测定结果,这些化合物预计将基本上没有通常的不良锥体外系副作用。它们可以通过常见的制备方法从公式III、IV或V的相应起始化合物中获得,或通过其他公式I的化合物的适当互变反应获得。如果需要,所得的碱可用适当的酸中和,优选甲磺酸、马来酸或盐酸,以得到相应的加合盐,可用于制备适当的剂量形式进行药理学评价和治疗应用。